Future antidepressants: what is in the pipeline and what is missing?

CNS Drugs
Fokko J BoskerJakob Korf

Abstract

Monoamine reuptake inhibitors still reign in the treatment of major depression, but possibly not for long. While medicinal chemists have been able to reduce the side effects of these drugs, their delayed onset of action and considerable non-response rate remain problematic. Of late, serious questions have been raised regarding the efficacy of monoamine reuptake inhibitors. The present review presents an inventory of what is (and until recently was) in the antidepressant pipeline of pharmaceutical companies. Novel antidepressant compounds can be categorised into four groups depending on their target(s): (i) monoamine receptors; (ii) non-monoamine receptors; (iii) neuropeptide receptors; and (iv) hormone receptors. Other possible targets include components of post-receptor intracellular processes and elements of the immune system; to date, however, compounds specifically aimed at these targets have not been the subject of clinical trials. Development of several compounds targeted at monoamine receptors has recently been discontinued. At least five neurokinin-1 (NK(1)) receptor antagonists were until recently in phase II of clinical testing. However, the apparent interest in the NK(1) receptor should not be interpreted as represen...Continue Reading

References

Feb 1, 1992·The British Journal of Psychiatry : the Journal of Mental Science·D P Doogan, V Caillard
Jan 25, 1991·Science·R M SniderR W Spencer
Jan 1, 1991·International Clinical Psychopharmacology·S H KennedyK Reed
Jan 1, 1990·Psychoneuroendocrinology·M MaesE Suy
Jan 1, 1990·Pharmacology & Toxicology·D S Janowsky, D H Overstreet
Jan 1, 1990·Pharmacology & Therapeutics·H van Riezen, B E Leonard
Jul 1, 1990·International Clinical Psychopharmacology·J P FeighnerV S Doroski
Jul 1, 1988·Journal of Neurochemistry·J M ArrangJ C Schwartz
Mar 1, 1989·Pharmacology, Biochemistry, and Behavior·M F PignatielloR D Olson
Jan 1, 1986·Progress in Neuro-psychopharmacology & Biological Psychiatry·P W GoldG P Chrousos
Dec 1, 1987·The American Journal of Psychiatry·T L PerseR Dar
Jul 1, 1988·International Clinical Psychopharmacology·M M Weber, H M Emrich
Nov 1, 1965·The American Journal of Psychiatry·J J Schildkraut
Aug 1, 1981·Canadian Journal of Physiology and Pharmacology·M WilliamsJ R Huff
Jul 1, 1981·Journal of Clinical Psychopharmacology·S C RischD S Janowsky
Aug 1, 1994·Archives of General Psychiatry·T SunderlandD L Murphy
Jul 4, 1995·European Journal of Pharmacology·T MatsudaA Baba
Aug 11, 1995·Science·M M Weissman, M Olfson
Feb 1, 1995·The Journal of Endocrinology·M P CareyE R de Kloet
Jan 1, 1994·Acta Psychiatrica Scandinavica. Supplementum·E K Syvälahti
Mar 1, 1994·Neuropharmacology·A L SharpleyP J Cowen
Aug 1, 1994·Journal of Affective Disorders·R H EhrensingA H Mebane
Apr 1, 1994·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R ArmitageH P Roffwarg
Jan 1, 1994·International Clinical Psychopharmacology·S A MontgomeryD Nutt
Jul 1, 1993·Trends in Pharmacological Sciences·F Artigas
Nov 1, 1993·The American Journal of Psychiatry·S C RibeiroJ F Greden
Jan 1, 1993·International Clinical Psychopharmacology·S A MontgomeryP Tanghøj
Jan 1, 1993·International Clinical Psychopharmacology·S A Montgomery, G Dunbar
Jan 1, 1993·Archives of General Psychiatry·K S KendlerR C Kessler
Mar 13, 1993·BMJ : British Medical Journal·F SongJ Mason
Dec 29, 1995·Annals of the New York Academy of Sciences·M A SmithR M Post
Sep 1, 1995·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·K V Harvey, R Balon
Jan 18, 1996·European Journal of Pharmacology·S W YingB Guardiola-Lemaitre

❮ Previous
Next ❯

Citations

Oct 2, 2008·Perspectives in Psychiatric Care·Debra Rose Wilson, Lita Warise
Jan 31, 2009·PloS One·Alessandro Bartolomucci, Rosario Leopardi
Nov 18, 2015·Iranian Journal of Psychiatry and Behavioral Sciences·Narges Shams AlizadehGholam Reza Esfandiari
May 11, 2006·The Australian and New Zealand Journal of Psychiatry·Trevor R Norman
Jul 6, 2006·Amino Acids·K Ebner, N Singewald
Jul 5, 2005·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller
Jun 1, 2010·Current Protocols in Pharmacology·Vincent CastagnéRoger D Porsolt
Jan 24, 2006·Nature Reviews. Neuroscience·Olivier Berton, Eric J Nestler
Mar 22, 2006·Expert Opinion on Therapeutic Targets·Guillaume J Hervieu
Jan 27, 2006·International Clinical Psychopharmacology·Eberhard FuchsBarthel Schmelting
Mar 21, 2009·Behavioural Pharmacology·Kenneth J SufkaJohn M Rimoldi
Mar 24, 2011·Journal of Pharmacological Sciences·Vanessa VillardTangui Maurice
Apr 5, 2011·Current Protocols in Neuroscience·Vincent CastagnéRoger D Porsolt
Jun 24, 2008·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Manisha JhambMark Unruh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Journal of Psychopharmacology
Oliver G BoschThomas C Wetter
The British Journal of Psychiatry : the Journal of Mental Science
Sepehr HafiziJ Cowen
© 2021 Meta ULC. All rights reserved